NCT00704639已完成1 期
A Phase II Study of Cetuximab, Carboplatin and Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
Trans Tasman Radiation Oncology Group1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Safety and Feasibility
研究概览
简要总结
This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin.
The aim of this study is to show the feasibility and safety profile of the combination of cetuximab, carboplatin and RT in treatment of patients with LAHNC.
详细描述
Secondary objectives are to estimate failure free survival (FFS) and overall survival, to evaluate the time to local and regional failure and to determine the site of first failure (characterised as local, regional, distant or combinations). Acute and late treatment toxicities will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously untreated SCC of the oropharynx, larynx or hypopharynx.
- •Stage III or IV, excluding T1N1, and metastatic disease (to be confirmed by a chest CT, and abdominal CT or ultrasound scan if patients with abnormal liver function tests or a bone scan or FDG-PET if patients with bone pain).
- •Histologically or cytologically confirmed HNSCC
- •Disease must be considered potentially curable by chemoradiation
- •Patients medically unfit for cisplatin chemotherapy due to one or more of the following reasons:
- •Clinically significant sensori-neural hearing impairment (audiometric abnormalities without corresponding clinical deafness will not be regarded as a contraindication to cisplatin)
- •Severe tinnitus
- •Renal impairment (GFR < 60ml/min)
- •Peripheral neuropathy > grade 2
- •Inability to tolerate intravenous hydration eg due to cardiac disease
- •Co-morbidities (based on clinical judgement by the investigator) associated with ECOG PS 2 that in the view of the investigator would preclude the safe administration of cisplatin
- •Performance status ECOG 0, 1 or
- •Adequate haematological, renal and hepatic functions as defined by:
- •Absolute neutrophil count (ANC, segmented cells (segs) + bands)>= 1.5 x 109/L
- •Platelet count >= 100 x 109/L
- •Total bilirubin <= 1.5 x upper normal limit
- •Alanine aminotransferase <= 2.5 x upper normal limit
- •Calculated creatinine clearance > 40ml/min (Cockcroft-Gault formula).
- •If calculated creatinine clearance < 50 ml/min, glomerular filtration rate to be measured with DTPA or EDTA scan. If < 40 ml/min not eligible.
- •Age >18 years
- •Signed written consent
- •Suitable for follow-up for 4 years in the view of the investigator
排除标准
- •Distant metastases, i.e., any metastatic disease below the clavicles. Patients with lung nodules >10mm will be excluded unless non-malignancy aetiology is established. Patients with lesions 5-10mm can be included if a FDG-PET scan is negative and the investigator considers on clinical grounds that metastasis is unlikely. Patients with lesions < 5mm can be included if the investigator considers on clinical grounds that metastases are unlikely. Patients with multiple lung nodules should not be included unless there is a strong case that these do not represent metastases, e.g., stable on imaging for over 12 months, non-malignant aetiology apparent. The level of clinical suspicion may be influenced by clinical stage, e.g., N3 disease, low neck nodes. In general if there is any doubt patients should be excluded.
- •Previous radical RT to the head & neck region, excluding superficial RT for a non-melanomatous skin cancer.
- •Patients with prior cancers, except: those diagnosed > 5 years ago with no evidence of disease recurrence and clinical expectation of recurrence of less than 5%; or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
- •Significant intercurrent illness that will interfere with the chemotherapy or radiation therapy such as HIV infection, cardiac failure, pulmonary compromise, active infection
- •Any history of myocardial infarction, ventricular arrhythmias, or unstable angina within the last 6 months
- •Pregnant or lactating women.
- •Weight loss greater than 20 % of usual body weight in the 3 months preceding trial entry
- •High risk for poor compliance with therapy or follow up as assessed by the investigator
- •Prior radiation to greater than 30% of the bone marrow
- •Prior systemic chemotherapy for cancer
- •Refusal by male or female patients, to use appropriate contraception during the study and for 3 months afterwards
- •Any condition or circumstance which might prevent the patient being able to give valid informed consent, or from completing participation in the study
研究组 & 干预措施
Single arm
Experimental
Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
干预措施: Cetuximab (Drug)
Single arm
Experimental
Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
干预措施: Carboplatin (Drug)
Single arm
Experimental
Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Safety and Feasibility
时间窗: An initial 6 patients will be treated. Once all these patients have a 2 week post RT review there will be analysis. If <= 1 patient has a DLT than the treatment is deemed safe.
次要结局
- Site of first failure(All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment.)
- Acute and late treatment toxicities(All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment.)
- Failure free survival (FFS)(All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment.)
- Time to local and/or regional failure(All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment.)
- Overall survival(All patients will be followed until the last patient enrolled has a minimum follow up of 2 years post treatment.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic CancerPancreatic CancerNCT00225784Dartmouth-Hitchcock Medical Center37
终止
2 期
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell CarcinomaClinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8KRAS Protein VariantPathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8NCT04106362Jonsson Comprehensive Cancer Center1
已完成
2 期
Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer TrialAdvanced Colorectal CancerNCT00386828British Columbia Cancer Agency43
已完成
2 期
Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00097214Eli Lilly and Company57
终止
1 期
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric CancerGastric CancerNCT01611506Dr Anna Dorothea Wagner1